Table of Contents
- Key Points
- Background: Why This Research Matters
- What Is Medullary Thyroid Carcinoma?
- The Imaging Challenge in MTC
- What Is SSTR PET/CT?
- How the Research Was Conducted
- Which Studies Were Included
- Characteristics of the Patients Studied
- Technical Details of the Imaging
- Risk of Bias and Study Quality
- Key Findings: Detection Rate and Clinical Impact
- Detailed Results of the Meta-Analysis
- The Link Between Calcitonin Levels and Detection
- What These Findings Mean
- How SSTR PET/CT Compares to Other Imaging
- Limitations of the Study
- What This Means for Patients
- Frequently Asked Questions
- Source Information
Key Points
- In 14 studies of 350 patients with recurrent or metastatic medullary thyroid carcinoma, SSTR PET/CT detected disease in 75.1% of cases.
- SSTR PET/CT is not a first-line scan; it is reserved for unclear conventional imaging, mismatched markers, or advanced metastatic disease.
- In six studies, the scan changed patient management in 16.6% to 100% of cases, most often by identifying PRRT candidates.
- Most studies found higher calcitonin levels were linked to higher detection rates, but only a minority formally tested this.
- DOPA PET/CT remains the most sensitive method for biochemical recurrence; SSTR PET/CT adds receptor information for PRRT eligibility.
Background: Why This Research Matters
Medullary thyroid carcinoma is a rare but aggressive form of thyroid cancer. Doctors need reliable imaging to find the disease when it returns or spreads. This research review asked a simple question: how well does a specific type of PET scan detect MTC?
The researchers also wanted to know whether this scan changes how doctors treat patients. The answer to both questions turned out to be encouraging.
This review is an update of an earlier analysis. It includes newer studies and more patients, which gives a clearer picture of how the technology performs in modern practice.
What Is Medullary Thyroid Carcinoma?
Medullary thyroid carcinoma (MTC) is a rare type of thyroid cancer. It accounts for only 1% to 8% of all thyroid cancers. Unlike the more common thyroid cancers, MTC is classified as a neuroendocrine tumor (a tumor that arises from hormone-producing cells).
MTC develops from parafollicular C cells in the thyroid gland. These cells produce two important proteins: calcitonin and carcinoembryonic antigen (CEA). Both proteins serve as key biological markers (substances in the blood that indicate disease activity) for MTC.
Most cases of MTC occur sporadically, meaning they appear without a known inherited cause. However, about 25% of cases are hereditary. These inherited cases run in families or occur as part of a syndrome called multiple endocrine neoplasia type 2. This syndrome results from mutations (changes) in a gene called the RET proto-oncogene.
MTC has a worse prognosis than other, more differentiated thyroid cancers. This is because MTC behaves more aggressively. At the time of diagnosis, up to 50% to 70% of patients already have cancer that has spread to lymph nodes in the neck. This typically appears as a painless lump or swelling in the neck.
Rising calcitonin levels can also signal that the cancer has spread to organs such as the lungs, bones, or liver. For this reason, finding the primary disease and any spread early is critical for choosing the right treatment.
The Imaging Challenge in MTC
Ultrasound is the first imaging test used to evaluate changes in the thyroid. If ultrasound findings need further investigation, doctors perform a fine needle aspiration biopsy (a procedure that removes a small sample of tissue with a thin needle).
Computed tomography (CT) and magnetic resonance imaging (MRI) can be used to look for regional or distant metastases (cancer that has spread to nearby lymph nodes or distant organs).
Nuclear medicine techniques offer a different approach. These techniques can detect molecular changes associated with MTC. They often find these changes before structural or morphological abnormalities become visible on conventional imaging.
Several conventional nuclear medicine imaging techniques have been explored for detecting MTC. However, their clinical usefulness has historically been limited by suboptimal sensitivity (the ability to correctly identify patients who have the disease).
Positron emission tomography (PET) offers superior spatial resolution compared with single-photon emission computed tomography (SPECT). Because of this advantage, several PET radiopharmaceuticals (radioactive tracers used for imaging) have been developed for MTC imaging.
Among these, two tracers are most widely used in clinical practice:
- [18F]fluorodihydroxyphenylalanine ([18F]DOPA) — a tracer that targets a specific metabolic pathway
- [18F]fluorodeoxyglucose ([18F]FDG) — a tracer that measures glucose (sugar) uptake by cells
These tracers are used particularly for restaging in patients with biochemical recurrence (rising blood markers after treatment) and rising serum calcitonin and/or CEA levels.
However, no single PET tracer provides optimal disease characterization across all clinical situations in MTC. This reflects the marked biological heterogeneity (diversity) of the disease.
What Is SSTR PET/CT?
Because MTC originates from neuroendocrine cells, researchers have investigated imaging that targets somatostatin receptors (SSTRs). These are proteins found on the surface of neuroendocrine cells. The imaging uses radioactive compounds called [68Ga]Ga-labeled DOTA-peptides.
Most MTCs express SSTRs, particularly a subtype called SSTR2A. However, the density of these receptors varies widely among patients. It is generally lower than in well-differentiated neuroendocrine tumors. This variability limits the routine clinical use of SSTR PET/CT.
As a result, SSTR PET/CT is not currently considered a first-line imaging method for MTC. It is generally reserved for specific clinical situations, including:
- Patients with negative or unclear results on conventional PET imaging
- Patients whose biochemical markers and imaging results do not match
- Patients with advanced metastatic disease
Importantly, the main value of SSTR PET/CT in MTC may lie less in its diagnostic superiority and more in its theranostic implications. Theranostics is an approach that combines diagnosis and therapy. SSTR PET/CT enables non-invasive whole-body assessment of SSTR expression. This may help identify patients who could benefit from peptide receptor radionuclide therapy (PRRT), a targeted treatment for advanced metastatic disease.
How the Research Was Conducted
The researchers performed a systematic review and meta-analysis of diagnostic accuracy. A systematic review collects and analyzes all relevant studies on a topic. A meta-analysis combines the numerical results of those studies into a single pooled estimate.
The team followed a rigorous, predefined protocol. The study adheres to PRISMA guidelines, which are international standards for reporting systematic reviews. The protocol was not registered in an external database because registration remains optional under Item 24 of the PRISMA guidelines.
The research team included several experts in SSTR PET/CT and MTC. It also included researchers with methodological expertise in conducting systematic reviews and meta-analyses.
To reduce the risk of selection bias, two reviewers independently carried out the literature search, study selection, data extraction, and quality appraisal. Any conflicts were resolved through collaborative group consensus.
The central review question was formulated using the PICO framework: "What is the diagnostic role of SSTR PET/CT in MTC, when compared or not compared to other imaging methods?"
The researchers searched three major medical databases: PubMed/MEDLINE, Scopus, and Embase. They used a combination of keywords and Boolean operators, including:
- "positron emission tomography" OR "PET"
- "DOTA" OR "SSTR"
- "medullary" OR "MTC"
No initial date restriction was applied. The search was updated through 1 April 2026. The researchers also manually screened the reference lists of all identified articles to capture any additional relevant publications.
For every included article, the researchers collected data on study features, technical variables, and patient characteristics. Study features included the first author's name, year of publication, country, funding source, and study design. Technical variables included the PET scanner used, type of radiopharmaceutical, mean tracer dose injected, uptake time, and kind of analysis. Patient characteristics included the number of patients, age, gender, and calcitonin level.
The methodological quality of the included studies was independently assessed using the QUADAS-2 tool. This validated instrument evaluates the risk of bias across four primary domains: patient selection, index test, reference standard, and flow and timing. Applicability concerns were also evaluated for the patient selection, index test, and reference standard domains.
For the statistical analysis, the researchers synthesized individual study data to determine the detection rate of MTC by SSTR PET/CT. They applied a random-effects model for statistical pooling and reported results with 95% confidence intervals using forest plots. Inter-study heterogeneity (how much the studies differed from each other) was quantified using the I² index. Values exceeding 50% signified significant heterogeneity. All calculations were performed using OpenMeta[Analyst] software.
Which Studies Were Included
The initial database searches identified 210 records after removing duplicates. After screening titles and abstracts, the researchers excluded:
- 99 records not related to the field of interest
- 10 reviews or editorials
- 78 case reports or small case series (fewer than 5 cases)
- 3 preclinical studies
Ultimately, 20 studies met the inclusion criteria for the systematic review. Of these, 14 studies were considered eligible for the meta-analysis. The other six studies were excluded from the meta-analysis because they lacked data on the detection rate of PET/CT or because the scan was performed for a different indication.
Manual reference tracking yielded no further eligible papers. All selection decisions reached full consensus among the two reviewers.
Characteristics of the Patients Studied
The 20 included studies were published between 2010 and 2025. The countries with the most studies were:
- Turkey (5 studies)
- United Kingdom (3 studies)
- Germany (3 studies)
- Brazil (2 studies)
- India (2 studies)
Funding sources were reported in only three studies. The majority of studies (74%) were retrospective, meaning they looked back at patient records rather than following patients forward in time.
Patient ages ranged from a median or mean of 42.9 to 63 years. Most studies showed a female predominance (more women than men were included).
The mean or median calcitonin level was very heterogeneous among studies, ranging from 133 to 6,671.6 pg/mL. This wide range reflects the different disease stages and burdens among the patient populations studied.
The studies served various purposes, including:
- Staging in patients with negative conventional imaging
- Comparison with FDG PET/CT in recurrent MTC
- Comparison with DOPA PET/CT in recurrent MTC
- Detection rate in recurrent MTC
- Comparison with other imaging methods (CT, MRI, bone scan, DMSA scintigraphy, and 111In-Octreotide scintigraphy)
- Correlation between tumor burden and tumor markers
- Eligibility assessment for PRRT
- Restaging in suspected relapse
- Prognostication
Technical Details of the Imaging
The studies used different radiopharmaceuticals (radioactive tracers). The most common was [68Ga]DOTA-TATE, used in 12 studies. The next most common was [68Ga]DOTA-NOC, used in 3 studies. In four studies, several radiopharmaceuticals were used. In one study, [18F]SiTATE was the selected radiotracer.
The average injected radiotracer activity varied considerably. When expressed as absolute activities, the administered activity ranged from 72 to 222 MBq (megabecquerels, a unit of radioactivity). When expressed as a relative value based on body weight, it ranged from 1.5 to 3 MBq/kg.
Consistently across all studies, the time between injection and scanning was approximately 60 minutes. The range was 45 to 90 minutes.
The PET/CT images were analyzed visually in all studies. In 12 articles, semiquantitative parameters were also used. These are numerical measurements that quantify tracer uptake. The most frequently used semiquantitative variable was SUVmax (maximum standardized uptake value), which measures the highest concentration of tracer in a tumor.
Risk of Bias and Study Quality
The overall assessment of risk of bias and concerns about applicability was evaluated using the QUADAS-2 tool.
For the "Patient Selection" domain, a significant proportion of studies were flagged with a high risk of bias. This was primarily due to their retrospective design and the inclusion of highly selective, heterogeneous patient groups. For example, some studies mixed patients with biochemical relapse (rising blood markers but no visible tumor) with patients who had known advanced metastatic disease.
In contrast, the "Index Test" and "Reference Standard" domains showed a low risk of bias or low applicability concerns across more than 80% of the analyzed papers. This reflects standardized PET/CT acquisition protocols and robust verification through histopathology (tissue examination) or clinical follow-up.
Key Findings: Detection Rate and Clinical Impact
The primary outcome assessed in the included studies was the diagnostic performance of SSTR PET/CT in recurrent MTC, metastatic MTC, or both.
Another field investigated was the potential impact on patient management, meaning both from a diagnostic and therapeutic point of view. This aspect was investigated in six studies. Management impact ranged from 16.6% to 100%. The highest impact was seen in the evaluation of distant localizations of disease.
The most important impact of SSTR PET/CT was to guide specific treatments, such as peptide receptor radionuclide therapy (PRRT). PRRT is a targeted treatment that delivers radiation directly to tumor cells that express somatostatin receptors.
Additionally, there was a strong relationship between calcitonin value and detection rate of PET/CT in most studies. In one article, a significant relationship between semiquantitative PET parameters (total tumor burden) and tumor markers was present.
Detailed Results of the Meta-Analysis
Fourteen studies including 350 patients with recurrent or metastatic MTC were selected for the quantitative meta-analysis.
The detection rate of MTC using SSTR PET/CT ranged from 33% to 93% across individual studies. The pooled (combined) detection rate was 75.1% with a 95% confidence interval of 67.6% to 82.6%.
This means that in about 3 out of every 4 patients, the scan successfully detected the disease. The confidence interval tells us that if this study were repeated many times, the true detection rate would fall between 67.6% and 82.6% in 95% of those repetitions.
There was moderate heterogeneity among the studies, as indicated by an I² value of 65.41%. This means that about 65% of the variation in results across studies was due to differences between the studies rather than chance alone.
To investigate potential publication bias (the tendency for studies with positive results to be published more often than studies with negative results), the researchers generated a funnel plot. Visual inspection of the plot revealed moderate asymmetry, suggesting some possibility of publication bias.
Individual study results varied widely. Here are the detection rates from the studies included in the meta-analysis:
- Conry et al. (2010, UK): 13 out of 18 patients (72%)
- Naswa et al. (2012, India): 42 out of 52 patients (81%)
- Treglia et al. (2012, Italy): 6 out of 18 patients (33%)
- Tran et al. (2015, UK): 6 out of 7 patients (86%)
- Traub-Weidinger et al. (2015, Austria): 6 out of 8 patients (75%)
- Ozkan et al. (2015, Turkey): 15 out of 22 patients (68%)
- Yamaga et al. (2017, Brazil): 14 out of 15 patients (93%)
- Audi Castroneves et al. (2018, Brazil): 5 out of 16 patients (31%) in the biochemical recurrence group; 13 out of 14 patients (93%) in the metastatic disease group
- Souteiro et al. (2019, Portugal): 9 out of 13 patients (69%)
- Sahin et al. (2020, Turkey): 10 out of 14 patients (71%)
- Asa et al. (2021, Turkey): 30 out of 46 patients (65%)
- Hayes et al. (2021, UK): 61 out of 71 patients (86%)
- Dadgar et al. (2023, Iran): 17 out of 20 patients (85%)
- Isik et al. (2025, Turkey): 14 out of 16 patients (87.5%)
One additional study (Ballal et al., 2023, India) reported detection rates by lesion type rather than by patient. The detection rates were:
- 94.4% for primary tumors
- 95% for lymph nodes
- 100% for brain metastases
- 68.9% for lung nodules
- 46.4% for liver metastases
- 76.5% for bone metastases
- 0% for pleural metastases
Regarding management impact, the studies that reported this outcome showed the following results:
- Treglia et al.: 3 out of 18 patients (16.6%) — the scan guided biopsy decisions
- Ozkan et al.: 18.2% — the scan guided surgery and PRRT
- Audi Castroneves et al. reported 6.25% in the biochemical recurrence group. Audi Castroneves et al. reported 35.7% in the metastatic disease group. The scan led to initiation of treatments such as bone antiresorptives, radiation therapy, or a change in radiological follow-up.
- Asa et al.: 68.4% — the scan guided surgery, PRRT, radiofrequency ablation (RFA), or combined treatment
- Ballal et al.: 68.9% — the scan guided treatment decisions
- Dadgar et al.: 20% — the scan guided PRRT
The Link Between Calcitonin Levels and Detection
Calcitonin is a hormone produced by the parafollicular C cells of the thyroid. In MTC, calcitonin levels in the blood serve as a tumor marker. Higher levels generally indicate more tumor tissue.
The researchers found a strong relationship between calcitonin value and detection rate of PET/CT in most studies. This means that when calcitonin levels were higher, the scan was more likely to find the disease.
However, only a minority of studies formally assessed this relationship with statistical analysis. One study (Naswa et al.) reported that a calcitonin level greater than 500 pg/mL was associated with significant findings on the scan. Another study (Sahin et al.) found a significant relationship between semiquantitative PET parameters (total tumor burden) and tumor markers.
This correlation makes biological sense. Higher calcitonin levels typically indicate a larger amount of tumor tissue. More tumor tissue means more cells expressing somatostatin receptors, which makes the tumor more visible on SSTR PET/CT.
What These Findings Mean
This updated systematic review and meta-analysis provides a comprehensive evaluation of the diagnostic performance and clinical utility of SSTR PET/CT in patients with MTC.
Twenty studies were selected for the systematic review, and 14 were selected for the meta-analysis. This represents an updated and extended version of a meta-analysis and systematic review previously published by Treglia and colleagues.
There is no general consensus regarding the use of nuclear medicine imaging in patients with MTC. However, recent recommendations from the European Association of Nuclear Medicine (EANM) support the use of PET/CT imaging techniques in patients with elevated MTC tumor marker levels after surgery. This is particularly relevant when morphological imaging (such as CT or MRI) is negative or inconclusive.
Notably, all included studies involved patients with increased median calcitonin levels. This provides a relevant clinical basis for assessing the diagnostic performance of SSTR PET/CT in patients with a high suspicion of recurrent disease.
In this meta-analysis, the researchers focused on the pooled detection rate. A meta-analysis of sensitivity and specificity was not feasible due to limited reporting and methodological heterogeneity across studies. In particular, insufficient data for reconstructing contingency tables and variability in patient-, lesion-, and region-based analyses precluded a reliable diagnostic accuracy analysis.
The pooled detection rate was 75% with acceptable consistency across studies (I² = 65.41%). This value is higher than that reported by Treglia and colleagues, which was 63.5%. The improvement likely reflects the inclusion of more recent studies and advancements in imaging technology. In the earlier study by Treglia and colleagues, only nine studies were included for a total of 152 patients.
Despite the high detection rate, approximately 21.5% of patients remained undetected. This may be explained by several factors:
- Heterogeneous SSTR2 expression (some tumors have fewer receptors than others)
- Low tumor burden (small amounts of disease may be below the detection threshold)
- Tumor dedifferentiation (tumors that have lost their neuroendocrine features may no longer express somatostatin receptors)
A significant contributor to the moderate inter-study heterogeneity (I² = 65.41%) is the difference in radiotracer selection and patient disease stages. The included studies utilized several radiopharmaceuticals, including 68Ga-labeled peptides (DOTATE, DOTANOC, DOTATOC). These may exhibit slightly different binding affinities across somatostatin receptor subtypes (SSTR2, SSTR3, and SSTR5). Furthermore, the recent introduction of the cyclotron-produced 18F-SiTATE introduces an entirely different radiopharmacokinetics profile (how the tracer moves through the body).
How SSTR PET/CT Compares to Other Imaging
To put these findings in context, it is essential to define where SSTR PET/CT fits in the diagnostic chart for MTC.
SSTR PET/CT is not considered a first-line diagnostic method for MTC. DOPA PET/CT remains widely recognized as the most sensitive functional imaging method for localizing disease in the setting of biochemical recurrence. [18F]FDG PET/CT plays a critical and complementary prognostic role.
Patients with high FDG uptake typically have biochemical progression, disease dedifferentiation, and aggressive tumor biology. This helps identify patients at high risk of rapid progression.
In this scenario, SSTR PET/CT might have the crucial role of identifying patients who are candidates for PRRT. Compared with other functional imaging methods, SSTR PET/CT demonstrated a good detection rate despite the lack of direct comparisons with other radiotracers.
A meta-analysis focused on [18F]DOPA PET/CT showed a detection rate of 66%. These methods should therefore be considered complementary. SSTR PET/CT may perform better in tumors with preserved receptor expression.
Limitations of the Study
This review has several limitations that patients and clinicians should understand.
First, the majority of included studies were retrospective. This means they looked back at existing patient records rather than following patients forward in time. Retrospective studies are more prone to selection bias than prospective studies.
Second, the patient populations were heterogeneous. Some studies included patients with biochemical recurrence (rising blood markers but no visible tumor), while others included patients with known advanced metastatic disease. This makes it difficult to compare results across studies.
Third, the studies used different radiopharmaceuticals. While most used [68Ga]DOTA-TATE, others used [68Ga]DOTA-NOC, [68Ga]DOTA-TOC, or [18F]SiTATE. These tracers may have different binding properties, which could affect detection rates.
Fourth, the researchers could not perform a meta-analysis of sensitivity and specificity. This was due to limited reporting and methodological heterogeneity across studies. Insufficient data for reconstructing contingency tables and variability in how results were analyzed prevented a reliable diagnostic accuracy analysis.
Fifth, there was moderate heterogeneity among studies (I² = 65.41%). This means that about 65% of the variation in results was due to differences between studies rather than chance. The funnel plot also revealed moderate asymmetry, suggesting possible publication bias.
Sixth, only a few studies formally assessed the relationship between serum calcitonin levels and the detection rate of SSTR PET/CT. While most studies suggested a correlation, only a minority performed statistical analysis.
Finally, the study protocol was not registered in an external database. While this is optional under PRISMA guidelines, registration can help reduce bias and improve transparency.
What This Means for Patients
If you or a loved one has been diagnosed with medullary thyroid carcinoma, here are the key takeaways from this research:
- SSTR PET/CT is a valuable problem-solving tool. It is not a first-line scan for everyone with MTC. However, it can be very helpful in specific situations, such as when conventional imaging is negative or unclear, or when blood markers and imaging results do not match.
- The scan detects disease in about 3 out of 4 patients. The pooled detection rate was 75.1%. This means that in about 75% of patients with recurrent or metastatic MTC, the scan successfully found the disease.
- The scan can change treatment decisions. In the studies reviewed, SSTR PET/CT influenced patient management in 16.6% to 100% of cases. The most important impact was identifying patients who could receive peptide receptor radionuclide therapy (PRRT).
- Higher calcitonin levels may improve detection. Most studies found a relationship between calcitonin levels and detection rate. If your calcitonin level is elevated, the scan is more likely to find the disease.
- SSTR PET/CT is complementary to other imaging methods. DOPA PET/CT remains the most sensitive method for localizing disease in biochemical recurrence. FDG PET/CT provides important prognostic information. SSTR PET/CT adds unique information about somatostatin receptor expression, which is essential for determining PRRT eligibility.
- Discuss with your care team. If you have MTC with rising tumor markers or suspected recurrence, ask your doctor whether SSTR PET/CT might be appropriate for your situation. The decision depends on your individual clinical circumstances.
It is important to remember that this research represents a summary of findings across many studies. Individual results may vary. Always discuss your specific situation with your healthcare provider.
Frequently Asked Questions
What is SSTR PET/CT and why would I need it for medullary thyroid carcinoma?
SSTR PET/CT is an imaging test that uses a radioactive tracer to target somatostatin receptors on neuroendocrine cells. In medullary thyroid carcinoma it is not a first-line scan. It is generally reserved for situations such as negative or unclear conventional PET results, blood markers and imaging that do not match, or advanced metastatic disease.
How often does SSTR PET/CT find medullary thyroid carcinoma that has returned or spread?
In a combined analysis of 14 studies and 350 patients with recurrent or metastatic medullary thyroid carcinoma, the scan detected disease in 75.1% of cases. Individual study results ranged from 33% to 93%. This means that in about 3 out of every 4 patients, the scan successfully found the disease.
Can SSTR PET/CT change my treatment plan?
Yes. In six studies that looked at this, SSTR PET/CT changed how doctors managed patient care in 16.6% to 100% of cases. The most important impact was identifying patients who could receive peptide receptor radionuclide therapy (PRRT), a targeted treatment for advanced metastatic disease. It also guided decisions about surgery, biopsy, radiation therapy, and other treatments.
Does a higher calcitonin level make the scan more likely to find the cancer?
Most studies found a strong relationship between calcitonin level and detection rate. When calcitonin levels were higher, the scan was more likely to find the disease. One study reported that a calcitonin level greater than 500 pg/mL was associated with significant findings. However, only a minority of studies formally tested this with statistical analysis.
What are the limitations of the research on SSTR PET/CT for medullary thyroid carcinoma?
Most included studies were retrospective, meaning they looked back at records rather than following patients forward. Patient groups were heterogeneous, and different radiopharmaceuticals were used. The researchers could not perform a meta-analysis of sensitivity and specificity. There was moderate heterogeneity among studies, and a funnel plot suggested possible publication bias.
If SSTR PET/CT is not first-line, how does it compare with other imaging for medullary thyroid carcinoma?
DOPA PET/CT remains widely recognized as the most sensitive functional imaging method for localizing disease in biochemical recurrence. FDG PET/CT provides important prognostic information about aggressive tumor biology. SSTR PET/CT adds unique information about somatostatin receptor expression, which is essential for determining PRRT eligibility. These methods are considered complementary rather than competing.
What should I discuss with my care team about SSTR PET/CT?
If you have medullary thyroid carcinoma with rising tumor markers or suspected recurrence, ask your doctor whether SSTR PET/CT might be appropriate for your situation. The decision depends on your individual clinical circumstances. This research summarizes findings across many studies, and individual results may vary. Always discuss your specific situation with your healthcare provider.
When should a patient with medullary thyroid carcinoma seek a second opinion about SSTR PET/CT imaging?
SSTR PET/CT is not a first-line scan for medullary thyroid carcinoma. It is reserved for specific situations: when conventional PET imaging is negative or unclear, when biochemical markers and imaging results do not match, or when advanced metastatic disease is present. The scan detected disease in about 3 out of 4 patients with recurrent or metastatic MTC and changed management in 16.6% to 100% of cases, most often by identifying candidates for peptide receptor radionuclide therapy. If your calcitonin is rising and imaging is inconclusive, an independent review can clarify whether this scan is appropriate. Diagnostic Detectives Network provides independent expert second opinions.
Source Information
Original Article Title: The Evolving Role of Somatostatin Receptor PET/CT in Medullary Thyroid Carcinoma: An Updated Systematic Review and Meta-Analysis.
Journal: Cancers
License: CC BY (open access)
Authors: Tasevski S, Imperiale A, Treglia G, Albano D.
Author Affiliations: Nuclear Medicine, University Institute for Positron Emission Tomography, Skopje, North Macedonia; Nuclear Medicine, University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland; Clinic for Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne, Switzerland; Department of Nuclear Medicine, Università degli Studi di Brescia, Brescia, Italy; Nuclear Medicine Department, ASST Spedali Civili of Brescia, Brescia, Italy
Publication: Cancers 2026, Volume 18, Article 2096
DOI: https://doi.org/10.3390/cancers18132096
Publication Dates: Received 11 May 2026; Revised 24 June 2026; Accepted 27 June 2026; Published 28 June 2026
Academic Editor: Sam Payabvash
Note: This patient-friendly article is based on peer-reviewed research. The original article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
